Skip to content
news
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results...
Oct 10, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize...
Oct 8, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for...
Oct 2, 2024
Company
About Lipocine
Management
Board of Directors
Corporate Governance
Careers
Pipeline & Product
Pipeline
LPCN 1154
LPCN 2101
LPCN 2401
LPCN 1148
LPCN 1107
LPCN 2203
LPCN 1154
LPCN 2101
LPCN 2401
LPCN 1148
LPCN 1107
LPCN 2203
Product
TLANDO®
TLANDO® Product Site
TLANDO®
TLANDO® Product Site
Technology
Li’pral Technology
Li’pral Technology
Investors/Media
Press Releases
Presentations/Events
SEC Filings
Investor FAQ
Contact
Address & Inquiries
Business Development
Linkedin-in
Search
Corporate Governance
Corporate Governance
Corporate Governance
Compensation Committee Charter
Code of Ethics & Business Conduct
Audit Committee Charter
Focus on enhancing health
We are pioneers of developing innovative drug products targeting significant unmet medical needs.